Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Marker Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MRKR
Nasdaq
8731
https://markertherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Marker Therapeutics Inc
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
- Apr 8th, 2024 11:00 am
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
- Mar 25th, 2024 9:45 pm
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Mar 22nd, 2024 4:30 pm
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
- Jan 22nd, 2024 12:30 pm
Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization
- Jan 8th, 2024 2:31 pm
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
- Jan 8th, 2024 1:24 pm
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
- Dec 21st, 2023 4:00 pm
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
- Dec 11th, 2023 12:00 pm
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Nov 9th, 2023 10:00 pm
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
- Oct 11th, 2023 2:27 pm
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Aug 30th, 2023 12:00 pm
Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance
- Aug 25th, 2023 4:07 pm
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
- Aug 17th, 2023 1:03 pm
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 14th, 2023 8:30 pm
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
- Aug 7th, 2023 11:00 am
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
- Jul 26th, 2023 11:00 am
Marker Therapeutics (NASDAQ:MRKR) hikes 26% this week, taking one-year gains to 95%
- Jul 22nd, 2023 12:12 pm
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
- Jul 10th, 2023 11:00 am
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
- Jun 26th, 2023 11:00 am
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
- Jun 12th, 2023 11:00 am
Scroll